Imagine owning one of the most successful drugs ever created. It generates $32 billion a year, accounts for nearly half of your company's sales, and has brought in more than $160 billion since its launch. Thanks to patent protection, no one can copy your recipe and sell a cheaper version. But that protection has an expiration date—and for Merck, it's fast approaching.
Merck's blockbuster cancer immunotherapy, Keytruda, will see its core patent protection begin to lapse in 2028. That opens the door to cheaper generic competitors, threatening a product that currently drives almost half of the company's revenue. The question for Merck—and for many other large drugmakers—is how to replace such a massive income stream. Welcome to the patent cliff.
What is the patent cliff?
The patent cliff refers to the steep drop in revenue that occurs when a drug's patent expires and generic versions flood the market. Generics are sold at a fraction of the price, quickly eroding the original drug's market share. For companies that rely heavily on a single blockbuster, the cliff can be devastating.
Merck is not alone. Many of the world's largest pharmaceutical companies are facing similar challenges as their own top-selling drugs lose protection. The industry has long known these dates are coming, but the pressure is now intensifying as the clock ticks down.
Why biotech acquisitions are the likely answer
To fill the revenue gap, big pharma is expected to go on a shopping spree for biotech companies with promising drug pipelines. Acquiring a smaller firm with a late-stage candidate—or a platform that can produce multiple drugs—offers a faster and more reliable path to new revenue than relying solely on internal research and development.
This is a familiar pattern. When faced with patent expiries, large drugmakers often turn to mergers and acquisitions to buy growth. The current environment makes this even more attractive: many biotech stocks have been under pressure, and valuations are relatively reasonable compared to the potential payoff of a successful drug.
Recent activity in the sector hints at this trend. For example, a supply-chain play for radiopharma shows how companies are positioning in specialized niches. Meanwhile, two biotechs have filed for Nasdaq IPOs, indicating that the capital markets are open for biotech—even as bond yields cloud the outlook for fall listings.
The patent cliff is not unique to Merck. Novo Nordisk faces patent cliff questions as its weight-loss drug Wegovy sees slowing growth. That company, too, will need to find new sources of revenue. The broader trend is clear: big pharma is preparing for a wave of expiries, and biotech acquisitions are a key part of the strategy.
What it means for investors
For everyday investors, this dynamic has several implications. First, biotech stocks could see increased interest as potential acquisition targets. Companies with strong pipelines, especially those in oncology, immunology, or rare diseases, may attract premium valuations from big pharma buyers.
Second, investors in large pharma companies should watch how management plans to address patent expiries. A well-executed acquisition strategy can help smooth the transition, but overpaying for a risky asset can destroy shareholder value. The market will be watching for signs of discipline.
Third, the broader healthcare sector may see a wave of consolidation. As big pharma seeks to replenish its pipelines, we could see more deals like the pharma boom that lifted Denmark's growth forecast—a reminder that drug development can have macroeconomic effects.
It's also worth noting that not all biotech acquisitions will succeed. The history of pharma M&A is littered with deals that failed to deliver. Investors should be cautious about chasing hype around potential targets, and instead focus on the fundamentals: the quality of the science, the size of the addressable market, and the likelihood of regulatory approval.
For those who own shares in big pharma, the key question is whether management can replace the lost revenue from patent expiries. The answer will likely come in the form of acquisitions—and the next few years could see a flurry of deals as companies race to secure their futures.
In the meantime, the patent cliff serves as a reminder that even the most successful products have a shelf life. For investors, staying informed about these dynamics is essential to navigating the healthcare sector.
